• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ProPhase Labs Inc. filed SEC Form 8-K: Leadership Update

    8/6/25 4:10:59 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRPH alert in real time by email
    false 0000868278 0000868278 2025-08-06 2025-08-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of

    The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): August 6, 2025

     

    PROPHASE LABS, INC.

    (Exact name of Company as specified in its charter)

     

    Delaware   000-21617   23-2577138

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    626 RXR Plaza, 6th Floor

    Uniondale, New York

      11556
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (516) 989-0763

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities Registered Pursuant to Section 12(b) of the Exchange Act:

     

    Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
    Common Stock, par value $0.0005   PRPH   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    (b) Departure of Chief Operating Officer

     

    On August 6, 2025, ProPhase Labs, Inc. (the “Company”) announced that Stu Hollenshead, Chief Operating Officer, notified the Company of his decision to resign from his position on July 31, 2025. The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Hollenshead will resume his prior role with the Company in the role as a marketing consultant.

     

    The Company plans to initiate a search to identify a successor. In the interim, the duties of the Chief Operating Officer will be shared among the executive management team.

     

    (c) Appointment of Fractional Chief Financial Officer

     

    On August 6, 2025, ProPhase Labs, Inc. (the “Company”) appointed Steven M. Plumb, CPA as its fractional Chief Financial Officer (“CFO”), effective immediately.

     

    Steven M. Plumb, CPA is a seasoned senior executive and financial manager experienced in operations, finance and marketing. He has Big 4 CPA experience, a background in IT, gaming, biotech, oil and gas, real estate, medical and utility companies. Mr. Plumb has served as the chief financial officer of numerous public companies over the course of his career as a fractional CFO. From April 2024 to August 2025, Mr. Plumb served as the chief financial officer of Driveitaway Holdings, Inc. (OTC:DWAY). From September 2023 to November 2024, Mr. Plumb served as the chief financial officer of A Game Beverages, Inc. From August 2022 to June 2024, Mr. Plumb served as the chief financial officer of Endexx Corp. (OTCBB:EDXC). From October 2020 to July 2023, Mr. Plumb served as the chief financial officer of Gaming Technologies, Inc. (OTCBB:GMGT). From January 2020 to March 2023, Mr. Plumb served as the chief financial officer of Directview Holdings, Inc. (OTCBB:DIRV). From January 2019 to October 2021, Mr. Plumb served as the chief financial officer of Artella Solutions, Inc. Since 2001, he has served as the owner and president of Clear Financial Solutions, a consulting firm that provides interim CFO services to small public companies. In this capacity he has prepared SEC filings, managed investor relations, raised capital, conducted mergers and acquisition activities, developed successful offering memorandum, registration statements and investor presentations. Mr. Plumb is a former auditor with PriceWaterhouseCoopers and KPMG. Mr. Plumb has a Bachelor of Business Administration degree from the University of Texas at Austin, Austin, Texas.

     

    Pursuant to his engagement, the Company entered into an agreement with Borosh Consulting, LLC dba Clear Financial Solutions (“CFS”), under which Mr. Plumb will provide fractional CFO services to the Company. The material terms of the engagement are that CFS will provide 25 hours of time per month at the rate of $10,000 per month, on a month-to-month basis.

     

    Mr. Plumb will be responsible for reviewing all SEC filings and the supporting documentation sufficient to give him comfort that the filings are complete and accurate. He will provide operational advice on streamlining operations, budgeting and cash flow projections, strategic direction, strategic planning, and capital markets advice.

     

    Ted Karkus, the Company’s CEO and Chairman of the Board, will continue to serve as the Company’s principal financial officer.

     

    Except as set forth above, there are no arrangements or understandings between Mr. Plumb and any other persons pursuant to which he was selected as an officer. Mr. Plumb does not have any family relationships with any director or executive officer of the Company, and there are no transactions in which he has an interest requiring disclosure under Item 404(a) of Regulation S-K.

     

    Forward-Looking Statements

     

    This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K other than statements of historical fact are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the Company’s ability to regain compliance with Nasdaq listing standards or receive additional time from Nasdaq to regain compliance if necessary. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and the negative of such terms or other similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements are based on the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

     

    2

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ProPhase Labs, Inc.
         
      By: /s/ Ted Karkus
        Ted Karkus
        Chairman of the Board and Chief Executive Officer

     

    Date: August 6, 2025

     

    3

     

    Get the next $PRPH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRPH

    DatePrice TargetRatingAnalyst
    1/14/2022$12.00 → $15.00Buy
    HC Wainwright & Co.
    12/20/2021$12.00Buy
    HC Wainwright & Co.
    10/13/2021Buy → Neutral
    Dawson James
    More analyst ratings

    $PRPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Hollenshead Stuart

    4 - ProPhase Labs, Inc. (0000868278) (Issuer)

    2/21/25 5:15:08 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Hollenshead Stuart

    3 - ProPhase Labs, Inc. (0000868278) (Issuer)

    2/21/25 5:00:11 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Gleckel Louis Md

    4 - ProPhase Labs, Inc. (0000868278) (Issuer)

    2/18/25 5:00:13 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on ProPhase Labs with a new price target

    HC Wainwright & Co. reiterated coverage of ProPhase Labs with a rating of Buy and set a new price target of $15.00 from $12.00 previously

    1/14/22 6:36:15 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on ProPhase Labs with a new price target

    HC Wainwright & Co. initiated coverage of ProPhase Labs with a rating of Buy and set a new price target of $12.00

    12/20/21 6:25:15 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase downgraded by Dawson James

    Dawson James downgraded ProPhase from Buy to Neutral

    10/13/21 10:48:44 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    SEC Filings

    View All

    SEC Form DEF 14A filed by ProPhase Labs Inc.

    DEF 14A - ProPhase Labs, Inc. (0000868278) (Filer)

    8/15/25 5:08:33 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by ProPhase Labs Inc.

    10-Q - ProPhase Labs, Inc. (0000868278) (Filer)

    8/13/25 5:07:36 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ProPhase Labs, Inc. (0000868278) (Filer)

    8/13/25 9:00:29 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biotech Stocks Rally as Oncology Market Targets $866B by 2034

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Despite alarming federal budget cuts that stand to potentially harm the national battle against cancer, it appears that the private sector continues to step up, with hundreds of millions of VC dollars pouring into oncology ventures so far in 2025. While there has been a recent victory in the Senate to restore $15 million for the Pancreatic Cancer Research Program (PCARP), the prior elimination of the only federal program dedicated solely to researching pancreatic cancer served as a stark reminder of these ongoing funding challenges. This dyn

    8/14/25 12:30:00 PM ET
    $IOBT
    $OLMA
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025

    ProPhase Delivers Significant Operational and Financial Improvements, Advances Multiple Non-Dilutive Liquidity Initiatives, and Targets Transformational Growth Catalysts Company granted key U.S. patent on BE-Smart™ Esophageal Adenocarcinoma Risk Assessment test (August 2025) Company to hold a virtual conference call Wednesday, August 13, 2025, at 2:00 PM ET UNIONDALE, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a diversified diagnostics, genomics, and consumer healthcare company, today reported financial and operational results for the three and six months ended June 30, 2025. Ted Karkus, CEO of ProPhase Labs, will present to s

    8/13/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment

    U.S. Patent No. 12379378-B2 protects biomarker-driven systems and methods to assess progression risk in Barrett's esophagus and esophageal adenocarcinoma; issuance follows the successful BE-Smart™ test validation (>95% technical success) and, together with BE-Smart's demonstrated compatibility with both brush and forceps biopsies, supports earlier detection. UNIONDALE, NY, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) (the "Company" or "ProPhase") today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12379378-B2 for the Company's biomarker-based systems and methods to assess progression risk in Barrett's esophagus and esophagea

    8/12/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Leadership Updates

    Live Leadership Updates

    View All

    Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

    6/18/25 11:19:00 AM ET
    $CATX
    $CGON
    $GALT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports

    GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and consumer products company, today announced the appointment of Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company's expansion into consumer-centered health and wellness products. As COO, Hollenshead will focus on accelerating ProPhase Labs' consumer-facing strategy, leveraging his deep expertise in direct-to-consumer growth, subscription models, digital marketing, and audience monetization to position the company as a leader in science-backed health solutions. The Company plans to provide additional updat

    2/18/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Unveils Project ZenQ-AI

    Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company's state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (W

    4/16/24 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Financials

    Live finance-specific insights

    View All

    ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025

    ProPhase Delivers Significant Operational and Financial Improvements, Advances Multiple Non-Dilutive Liquidity Initiatives, and Targets Transformational Growth Catalysts Company granted key U.S. patent on BE-Smart™ Esophageal Adenocarcinoma Risk Assessment test (August 2025) Company to hold a virtual conference call Wednesday, August 13, 2025, at 2:00 PM ET UNIONDALE, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a diversified diagnostics, genomics, and consumer healthcare company, today reported financial and operational results for the three and six months ended June 30, 2025. Ted Karkus, CEO of ProPhase Labs, will present to s

    8/13/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025

    UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase"), a next generation biotech, genomics and consumer products company, announced today that they will be presenting second quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on August 13, 2025, at 2:00 pm EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register using the link below. After the event, a re

    8/11/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025

    Highlights Multiple Significant Potential Liquidity Events Anticipated Within the Next Few Months Completes Significant Reductions in Overhead and Expenses BE-Smart Esophageal Cancer Test Study has been Submitted in the Journal of Clinical Gastrointestinal Hepatology Company to hold a virtual conference call Tuesday, May 20, 2025, at 10:00 AM ET GARDEN CITY, NY, May 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today reported its financial and operational results for Q1 ended March 31, 2025, and outlined significant strategic corporate developments. Ted Karkus, CEO of ProP

    5/20/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

    SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

    3/19/24 4:18:00 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

    SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

    4/5/23 4:37:55 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

    SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

    4/4/23 4:25:33 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care